Analyst Julian Harrison of BTIG reiterated a Buy rating on Apogee Therapeutics, retaining the price target of $115.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julian Harrison’s rating is based on the promising clinical developments and potential of Apogee Therapeutics’ APG777, particularly in the treatment of atopic dermatitis, asthma, and eosinophilic esophagitis. The narrowing timelines for clinical data and the anticipated best-in-class features of APG777 suggest significant upside potential for the company’s stock.
The expected confirmation of APG777’s efficacy and safety profile, along with the ongoing trials and data updates, further support the Buy rating. Additionally, the company’s strategic financial moves, such as the public offering, are incorporated into the valuation model, reinforcing the positive outlook. Harrison views the conjunctivitis debate as a buying opportunity, given the favorable comparison of APG777 to existing treatments like Dupixent.
Harrison covers the Healthcare sector, focusing on stocks such as Oruka Therapeutics, Nektar Therapeutics, and United Therapeutics. According to TipRanks, Harrison has an average return of 27.9% and a 50.65% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $82.00 price target.